Randomized controlled trial to evaluate the prediction of the immunotherapy response based on HLA-type.

Interventions: R0: Gastrectomy alone Chemotherapy: F/MF PSK group: F/MF and PSK R(+) Chemotherapy: MF/CF PSK group: MF/CF and PSK PSK was administered orally from 14 days after gastrectomy at a dose of 3.0g/day and at least at a dose of over 270g. Fluoropyrimidine prodrug (5-FU 150mg/day or UFT (300mg/day or TS1 40-80mg/day) was administered orally from 14 days after gastrectomy over 1 year. MMC was injected intravenously 0.4 mg/Kg and/or 0.2 mg/Kg intraoperatively within 1 month after gastrectomy. CDDP (40-60mg/m2/W 4 times) was administered intravenously after gastrectomy starting from July 1996. PSK(-) PSK(+) Primary outcome(s): Evaluation of overall survival and QOL in patients given therapies with or without PSK based on HLA category types. Study Design: Parallel Randomized